profit from every $100 of sales.
$0$100
AIM ImmunoTech
$0.16+1.29% today
-90.1% in 1 year
1-year low $0.151-year high $1.59
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What AIM ImmunoTech sold, what it kept, and what it did with the cash.
Sales went from $141,000 in 2022 to $88,000 in 2025, with -$14.0 million of profit last year.
SalesProfit
AIM ImmunoTech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| AIM ImmunoTech | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads AIM ImmunoTech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | -0 | |
| -20 | -32 | -20 | -12 | |
| -20 | -29 | -16 | -13 | |
| -19 | -29 | -17 | -14 | |
| -39.96 | -59.94 | -30.92 | -8.62 | |
| 100.0% | 79.2% | 81.8% | -45.5% | |
| -14,129.8% | -15,800.0% | -11,630.6% | -13,254.5% | |
| -13,790.8% | -14,337.6% | -10,188.2% | -15,861.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 40 | 19 | 9 | 6 |
| Cash | 27 | 5 | 2 | 3 |
| Total debt | 1 | 1 | 3 | 5 |
| Total liabilities | 2 | 9 | 10 | 16 |
| 38 | 10 | -1 | -10 | |
| 0 | 0 | 1 | 2 | |
| -40.0% | -208.9% | -816.6% | – | |
| -50.5% | -283.0% | 1,310.1% | 142.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -16 | -21 | -15 | -11 | |
| 0 | 1 | 1 | 0 | |
| -16 | -22 | -15 | -11 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 0 | 1 | 0 |
Valuation
- –
- –
- –
- -0.1×
- 71.2×
- –
- –
- -181.0%
- -222.8%
- 0.0%
Profitability
- -45.5%
- -13,254.5%
- -15,861.4%
- -13,180.7%
- -331.9%
- -226.3%
- 212.6%
- -241.4%
- 2,520.6%
- 3,958.0%
Growth
- −14.5%
- –
- +26.5%
- –
- +5.5%
Financial health
- –
- -0.50
- 84.7%
- -13.7×
- 0.53
- 0.53
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 868
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.69 | -0.53 | −30.2% |
| Mar 27, 2026 | -0.44 | -0.94 | +53.2% |
| Nov 17, 2025 | -1.57 | -0.97 | −61.0% |
| Aug 14, 2025 | -3.68 | -8.00 | +54.0% |
| May 15, 2025 | -5.00 | -8.00 | +37.5% |
| Mar 27, 2025 | -10.00 | -9.00 | −11.1% |
| Nov 14, 2024 | -6.00 | -10.00 | +40.0% |
| Aug 14, 2024 | -3.00 | -0.12 | −2,400.0% |
News
BKV targets 400 MW Temple phase 1 as it continues to aim for a PPA in 2026 to early 2027Seeking Alpha · Nov 6, 2026GOOGL's $250B AI Chip Opportunity Takes Aim At NVDA — Beth Kindig Says Google Is Going After ‘One Of The Most Profitable Hardware Businesses’Yahoo Finance · Oct 25, 2026Walmart takes aim at Amazon and Costco with new membership program — but is it a good deal?MarketWatch · Oct 20, 2026'Real boss of India?': Elon Musk takes aim at Indian billionaire Ambani as Starlink launch stallsCNBC · Oct 9, 2026AMD's $8.2 Billion AI Deal Takes Aim at Nvidia's Biggest AdvantageYahoo Finance · Sep 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/5Passes 0 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
1No pass
Philip Fisher
25No pass
Peter Lynch
–Not enough data
Joel Greenblatt
–Not enough data
Charlie Munger
44No pass
Terry Smith
43No pass
Questions about AIM ImmunoTech
Is AIM ImmunoTech a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AIM ImmunoTech AI analysis
What does AIM ImmunoTech do?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. It is in Biotechnology.
Does AIM ImmunoTech pay a dividend?
No. AIM ImmunoTech does not pay a dividend at the moment.
Is AIM ImmunoTech stock halal?
No. AIM ImmunoTech does not pass our halal screen: its debt is 78% of its market value, at or above the 33% limit. How we check
How has AIM ImmunoTech stock done over the past year?
Down 90.1% over the past twelve months, to $0.16. It traded between $0.15 and $1.59 and is 90.1% below its high.
Who are AIM ImmunoTech's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with AIM ImmunoTech's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.